The head of the maker of remdesivir, an anti-viral shown to reduce recovery times in Covid-19 patients, said the company has been exporting the drug and is making it available to patients in the United States through the government, AFP reported.
Gilead Sciences CEO Daniel O'Day said the company is donating its entire existing supply of the drug — 1.5 million vials, enough to treat 100,000 to 200,000 patients.
“We have been exporting for clinical trials and for compassionate use thousands of treatment courses,” O'Day said on CBS's Face the Nation.
